Combining 9MW2821 and Toripalimab for advanced urothelial cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and effectiveness of 9MW2821 in combination with Toripalimab in patients with local advanced or metastatic urothelial cancer. It is an open-label, multicenter study that aims to assess various factors including pharmacokinetics and immunogenicity. Participants will be monitored for their response to the treatment and any potential side effects. The study includes patients who have previously received standard therapy or have not been treated before.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Sign and date the informed consent form e approved by independent ethics committe.
* Male or female subjects aged 18 to 80 years (including 18 and 80 years).
* ECOG status of 0 or 1.
* Histologically or cytologically confirmed local advanced or metastatic urothelial cancer
* Subjects have received at least 1 line advanced standard therapy or were not treated before
* Subjects must submit tumor tissues for test
* Life expectancy of ≥ 12 weeks.
* Subjects must have measurable lesions according to RECIST (version 1.1).
* Adequate organ functions
* Sexually active fertile subjects, and their partners, must agree to use methods of contraception during the study and at least 6 months after termination of study therapy.
* Subjects are willing to follow study procedures.

Exclusion Criteria:

* Anti-tumor treatment such as chemotherapy and radiotherapy within 21 days prior to the first dose of study drug.
* Major surgery within 28 days prior to first dose of study drug.
* PD-1/PD-L1/PD-L2 inhibitors used in the previous treatment for La/m UC.
* Previous treatment with ADCs conjugated with MMAE payload.
* Clinical significantly toxicity Grade ≥ 2 (except alopecia and pigmentation) related to previous treatment.
* Peripheral neuropathy Grade ≥ 2.
* Poorly controlled blood sugar.
* Increased risks of corneal disease assessed by the investigator prior to the first dose of study drug.
* Documented history of clinically significant cardiac or cerebrovascular diseases within 6 months prior to the first dose of study drug.
* Active infections, such as uncontrolled HBV/HCV/HIV/TB infection, etc.
* Other serious or uncontrolled diseases, such as serious interstitial pneumonia/asthma, serious thromboembolic events, etc.
* Poorly controlled central nervous system metastases.
* Organ transplantation or allogeneic hematopoietic stem cell transplantation in the past.
* History of drug abuse or mental illness.
* Known allergic sensitivity to any of the ingredients of the study drug.
* Any P-glycoprotein (P-gp) inducers/inhibitors or potent CYP3A4 inducers/inhibitors within 14 days prior to the first dose of study drug.
* History of autoimmune disease requiring systemic treatment within 2 years before the first dose.
* Any live vaccines within 4 weeks before first dose of study drug or during the study.
* Use of any investigational drug or medical instruments within 28 days prior to the first dose of study drug.
* History of another malignancy within 3 years before the first dose of study drug. Subjects with curable malignancies are allowed.
* Other conditions unsuitable into the study.

Where it's running

• Beijing Cancer Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Jun Guo, Professor
• Email: guoj307@126.com
• Phone: 010-88196358

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rimegepant plus toripalimab in advanced urothelial cancer after standard therapy

  This small, early-stage study tests whether combining rimegepant with toripalimab is safe and shows signs of activity in adults with advanced urothelial cancer that did not respond to prior treatment.

  Recruiting at 2 sites Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality and 1 other locations · NCT07835035

• TMV vaccine alone or with toripalimab for recurrent head and neck cancer

  This study tests a personalized TMV vaccine, alone and with toripalimab, in adults whose head and neck cancer has returned and is planning salvage surgery.

  Recruiting Phase 1 Metaclipse Therapeutics Corporation · Houston, Texas · NCT07898124

• Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer

  This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07896681

• Propranolol with Toripalimab and Platinum Chemo before/around surgery in NSCLC

  This study tests whether adding propranolol to toripalimab and platinum-based chemotherapy is safe and tolerable for people with resectable non-small cell lung cancer before surgery.

  Recruiting Phase 1 Second Xiangya Hospital of Central South University · Changsha, Hunan and 3 other locations · NCT07886229

• Neoadjuvant Cryo-Thermal Ablation with Toripalimab and Chemo for Resectable NSCLC

  This study tests whether using Cryo-Thermal Ablation before chemo-immunotherapy helps people with resectable NSCLC see better outcomes.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan and 8 other locations · NCT07855965

• SABR with Axitinib and Toripalimab for oligometastatic kidney cancer

  This phase 2 trial tests whether giving SABR radiation together with axitinib and toripalimab can shrink tumors and help patients with up to five metastatic sites from clear cell renal cell carcinoma.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT07744932

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.